tbuckley/cabot-search huggingface dataset:
<i>MET</i> DNA Alterations in NSCLC—Reply
Authors: Joanna H.M. Tong, Anthony W.H. Chan, Ka F. To
Journal: Clinical Cancer Research (2016)

We thank Mengoli and colleagues for their interest in our article (1) and their comprehensive review of METΔ14-positive pulmonary sarcomatoid carcinomas (PSC) been reported in the literature. We agree with their observation that METΔ14 seems to be associated with the presence of adenocarcinoma component.Of the 7 METΔ14-positive PSCs in our series, 5 contain adenocarcinoma components admixed with sarcomatous components (giant cell or spindle cell). These include four with adenocarcinoma (TTF-1 positive) and one with adenosquamous cell carcinoma (ADSQ, TTF-1, p40, and p63 positive). These 5 cases can be classified as pleomorphic carcinoma according to the 2015 WHO classification of lung tumors (2). For the other two METΔ14-positive tumors, one shows pure giant cell morphology but exhibits focal positivity for TTF-1. Although focal TTF-1 expression might suggest the differentiation toward adenocarcinoma, we diagnosed this tumor as giant cell carcinoma rather than pleomorphic carcinoma due to the absence of adenocarcinoma morphology. The remaining METΔ14-positive tumor is a pure spindle cell carcinoma that is positive for cytokeratin and negative for TTF-1.An interesting observation of our cases is the presence of METΔ14 in both epithelial and sarcomatous components in four pleomorphic carcinomas that we analyzed the two components separately (unpublished data), suggesting the clonal origin of the two components. However, in two tumors with concomitant METΔ14 and high-level MET amplification, MET amplification is found in sarcomatous component only but not in epithelial elements (case #4 and #16 in Supplementary Table S2 of the original article; ref. 1). This is in keeping with the monoclonal theory of biphasic tumors (3) and the sarcomatous elements might derive from the carcinoma during the evolution of the tumor.In keeping with other studies (4) that METΔ14 associates with adenocarcinoma component, 5 of 7 PSCs in our series contain adenocarcinoma component. METΔ14 can also be found in pure giant cell (n = 1) and spindle cell carcinoma (n = 1). Although there is no statistically significant association between the presence of adenocarcinoma component and METΔ14 (Table 1, P = 0.074) in PSC, a trend toward higher frequency of METΔ14 in PSC with adenocarcinoma component is noticed. However, we do demonstrate that the presence of TTF-1 expression is significantly associated with METΔ14 in PSC (P = 0.020). In clinical practice, only small biopsies are available for pathologic evaluation in most of the advanced cancers. The presence of any sarcomatoid component should alert the clinician for the possibility of METΔ14 mutation.See the original Letter to the Editor, p. 3697No potential conflicts of interest were disclosed.
Can Tuberculosis be Eradicated?
Authors: B van Vliet
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Increased Fragmentation of von Willebrand Factor, Due to Abnormal Cleavage of the Subunit, Parallels Disease Activity in Recurrent Hemolytic Uremic Syndrome and Thrombotic Thrombocytopenic Purpura and Discloses Predisposition in Families
Authors: Miriam Galbusera, Marina Noris, Chiara Rossi, Silvia Orisio, Jessica Caprioli, Zaverio M. Ruggeri, Barbara Amadei, Piero Ruggenenti, Beatrice Vasile, Giorgio Casari, Giuseppe Remuzzi
Journal: Blood (1999)
In vivo biodistribution studies and ex vivo lymph node imaging using heavy metal-free quantum dots
Authors: Elnaz Yaghini, Helen D. Turner, Alix M. Le Marois, Klaus Suhling, Imad Naasani, Alexander J. MacRobert
Journal: Biomaterials (2016)

Quantum dots (QDs) are attractive photoluminescence probes for biomedical imaging due to their unique photophysical properties. However, the potential toxicity of QDs has remained a major obstacle to their clinical use because they commonly incorporate the toxic heavy metal cadmium within the core of the QDs. In this work, we have evaluated a novel type of heavy metal-free/cadmium-free and biocompatible QD nanoparticles (bio CFQD(®) nanoparticles) with a good photoluminescence quantum yield. Sentinel lymph node mapping is an increasingly important treatment option in the management of breast cancer. We have demonstrated their potential for lymph node mapping by ex vivo imaging of regional lymph nodes after subcutaneous injection in the paw of rats. Using photoluminescence imaging and chemical extraction measurements based on elemental analysis by inductively coupled plasma mass spectroscopy, the quantum dots are shown to accumulate quickly and selectively in the axillary and thoracic regional lymph nodes. In addition, lifetime imaging microscopy of the QD photoluminescence indicates minimal perturbation to their photoluminescence properties in biological systems.
Present Status of Chemotherapy of Cancer by Regional Perfusion
Authors: E T KREMENTZ
Journal: CA A Cancer Journal for Clinicians (1961)

chemotherapy of cancer by regional perfusion with the heartâ€"lungmachine began at your institution.What has your experience been so far? DR. KREMENTZ:Our experimental work with this technique began early in 1957 and our first patient was treated in June of that year.Since that time, we have perfused 317 patients with malignant dis ease on 373 occasions.
West Nile Virus
Authors: Janet M. Torpy
Journal: JAMA (2003)

West Nile VirusW est Nile virus (WNV) affects humans, birds, horses, and other animals.The virus is carried from infected birds (the host animal) to humans and other mammals through mosquito bites.When a mosquito bites, a small amount of blood is injected into the skin of the bitten person or animal.This infected blood can transmit WNV or other similar diseases.West Nile virus is more commonly found in the eastern United States.West Nile virus disease activity has spread rapidly since 1999, when it was first reported in the United States.The main period of risk is from July through September, but cases have occurred from May through December.The outbreak of WNV infection in the United States during the summer of 2002 was the largest reported.There were 284 deaths and 4156 human cases of WNV infection reported in 2002.The July 23/30, 2003, issue of JAMA includes articles about WNV.
EGFR mutation analysis in histologic and cytologic specimens of non-small cell lung cancer
Authors: H. Sakai, K. Akagi, J. Sudoh, S. Yoneda, H. Komagata, F. Kurimoto, Y. Hommura
Journal: Journal of Clinical Oncology (2006)

7176 Background: Recent studies have suggested that EGFR mutations can be used to predict tumor sensitivity to gefitinib (epidermal growth factor receptor tyrosine kinase inhibitor) in patients with non-small-cell lung cancer (NSCLC). Most previous studies of EGFR mutations have used direct sequencing to analyze surgically resected specimens. More rapid, accurate, and simple techniques for analysis of EGFR mutations in histologic or cytologic specimens (i.e., transbronchial biopsy, bronchial washing, pleural effusion, lymph node aspiration) are needed to improve outcomes. Methods: DNA was extracted from histologic or cytologic specimens of NSCLC obtained from March through October 2005. The major mutations of the EGFR gene (exons 18–21) were analyzed by our original technique for fragment analysis and polymerase-chain-reaction-restriction-fragment-length polymorphism analysis. Results: About 2 days were required for mutation analysis. Pathological analysis indicated that 64 (5 histologic and 59 cytologic specimens) of 90 specimens (11 histologic and 79 cytologic specimens) were adenocarcinomas. EGFR mutations were found in 22 of these specimens (2 histologic and 20 cytologic specimens; ex19:del 13, ex19:ins 2, ex21:L858R 7). An EGFR mutation (ex19:del) was also found in a patient with large cell carcinoma. Conclusions: Our method can efficiently detect EGFR mutations in small samples of lung cancer cells obtained from histologic or cytologic specimens. This method is useful for the identification of EGFR mutations in patients with unresectable NSCLC in whom sufficient tissue specimens are difficult to obtain. No significant financial relationships to disclose.
Double Cord Blood Transplantation: Incidence, Organ Involvement and Risk Factors of Acute Graft Versus Host Disease. a Retrospective Analysis on Behalf of Eurocord, ALWP and Cqwp-EBMT
Authors: Erick Xavier, Annalisa Ruggeri, Myriam Labopin, Didier Blaise, Patrice Chevallier, Nathalie Fegueux, Jan J. Cornelissen, Eric Deconinck, Mauricette Michallet, Gerard Socie, Mohamad Mohty, Henrik Sengeloev, Dimitrios Karakasis, Lionel Mannone, Noel Milpied, Arnon Nagler, Natacha Maillard, Laurence Clement, Jean-Yves Cahn, Jacques-Olivier Bay, Thierry Lamy, Eefke J Petersen, Grant McQuaker, Charles Craddock, Jean-Henri Bourhis, Johanna Tischer, Chantal Kenzey, Fernanda Volt, Federica Giannotti, Eliane Gluckman, Rafael F. Duarte, Vanderson Rocha
Journal: Blood (2014)
Visual Acuity Loss and Associated Risk Factors in the Retrospective Progression of Stargardt Disease Study (ProgStar Report No. 2)
Authors: Xiangrong Kong, Rupert W. Strauss, Michel Michaelides, Artur V. Cideciyan, José-Alain Sahel, Beatriz Muñoz, Sheila West, Hendrik P.N. Scholl, Hendrik P.N. Scholl, Rupert W. Strauss, Yulia Wolfson, Millena Bittencourt, Syed Mahmood Shah, Mohammed Ahmed, Etienne Schonbach, Kaoru Fujinami, Elias Traboulsi, Justis Ehlers, Meghan Marino, Susan Crowe, Rachael Briggs, Angela Borer, Anne Pinter, Tami Fecko, Nikki Brugnoni, Janet S. Sunness, Carol Applegate, Leslie Russell, Michel Michaelides, Anthony Moore, Andrew Webster, Sophie Connor, Victoria McCudden, Maria Pefkianaki, Jonathan Aboshiha, Gerald Liew, Graham Holder, Anthony Robson, Alexa King, Daniela Ivanova Cajas Narvaez, Katy Barnard, Catherine Grigg, Hannah Dunbar, Yetunde Obadeyi, Karine Girard-Claudon, Hilary Swann, Avani Rughani, Charles Amoah, Dominic Carrington, Kanom Bibi, Emerson Ting Co, Andrew Carter, Anne Georgiou, Selma Lewis, Saddaf Shaheen, Harpreet Shinmar, Linda Burton, Paul Bernstein, Kimberley Wegner, Briana Lauren Sawyer, Bonnie Carlstrom, Kellian Farnsworth, Cyrie Fry, Melissa Chandler, Glen Jenkins, Donnel Creel, David Birch, Yi-Zhong Wang, Luis Rodriguez, Kirsten Locke, Martin Klein, Paulina Mejia, Artur V. Cideciyan, Samuel G. Jacobson, Sharon B. Schwartz, Rodrigo Matsui, Michaela Gruzensky, Alejandro J. Roman, Eberhart Zrenner, Fadi Nasser, Gesa Astrid Hahn, Barbara Wilhelm, Tobias Peters, Benjamin Beier, Tilman Koenig, Susanne Kramer, José-Alain Sahel, Saddek Mohand-Said, Isabelle Audo, Caroline Laurent-Coriat, Ieva Sliesoraityte, Christina Zeitz, Fiona Boyard, Minh Ha Tran, Mathias Chapon, Céline Chaumette, Juliette Amaudruz, Victoria Ganem, Serge Sancho, Aurore Girmens, Hendrik P.N. Scholl, Rupert W. Strauss, Yulia Wolfson, Syed Mahmood Shah, Mohammed Ahmed, Etienne Schonbach, Robert Wojciechowski, Shazia Khan, David G. Emmert, Dennis Cain, Mark Herring, Jennifer Bassinger, Lisa Liberto, Sheila West, Ann-Margret Ervin, Beatriz Munoz, Xiangrong Kong, Kurt Dreger, Jennifer Jones, Srinivas Sadda, Anamika Jha, Alex Ho, Brendan Kramer, Amirhossein Hariri, Gloria Rebecca Blanquel, Ngoc Lam, Sean Pitetta, Yue Shi, Rita Tawdros, Christine Petrossian, Dennis Jenkins, Muneeswar Gupta, Yong Dong Zhou, Katherine Aguilar, Cynthia Chan, Lisa Santos, Brian Seo, Christopher Sison, Silvia Perez, Stephanie Chao, Kelly Miyasato, Julia Higgins, Zoila Luna, Anita Menchaca, Norma Gonzalez, Vicky Robledo, Karen Carig, Kirstie Baker, David Ellenbogen, James Russell, Daniel Bluemel, Alex Moreno, Royal Pham, Theo Sanford, Daisy Linares, Mei Tran
Journal: Ophthalmology (2016)
211P Early tumor shrinkage (ETS) and depth of response (DpR) in patients with advanced gastric cancer (AGC) receiving S1 plus cisplatin (SP) or capecitabine plus cisplatin (XP)
Authors: N. Sugimoto, T. Yoshinami, S. Yamamoto, T. Yagi, F. Imamura
Journal: Annals of Oncology (2015)
Trisodium Nitrilotriacetate Monohydrate: Promoting Effects on the Development of Renal Tubular Cell Tumors in Rats Treated With &lt;italic&gt;N&lt;/italic&gt;-Ethyl-&lt;italic&gt;N&lt;/italic&gt;-hydroxyethylnitrosamine&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;
Authors: Y Hiasa, Y Kitahori, N Konishi, N Enoki, T Shimoyama, A Miyashiro
Journal: JNCI Journal of the National Cancer Institute (1984)

The effect of trisodium nitrilotriacetate monohydrate [N,N-bis(carboxymethyl)glycine trisodium salt] (Na3NTA X H2O) on development of renal tubular cell tumors induced with N-ethyl-N-hydroxyethylnitrosamine [CAS:13147-25-6; 2-(ethylnitrosamino)-ethanol] (EHEN) was studied. Six-week-old male inbred W rats were given a diet containing 1,000 ppm of EHEN for 2 weeks and then a diet containing a high (10,000 ppm) or low (500 ppm) concentration of Na3NTA X H2O for 30 weeks. The rats were killed during week 32. The higher concentration of Na3NTA X H2O enhanced the development of renal tubular cell tumors and increased the number and size of tumors in rats treated with EHEN, but the lower concentration of Na3NTA X H2O did not. The incidence of renal tubular cell tumors in week 32 was 33% in rats treated with 1,000 ppm EHEN for 2 weeks, 100% in rats treated with 1,000 ppm EHEN for 2 weeks plus high Na3NTA X H2O diet for 30 weeks, and 39% in rats treated with 1,000 ppm EHEN for 2 weeks and then given low Na3NTA X H2O diet for 30 weeks. Numbers of atypical cell foci per kidney area (No./cm2) were 17.0 +/- 7.6 in rats treated with EHEN and high Na3NTA X H2O, 7.3 +/- 2.2 in rats treated with EHEN and low Na3NTA X H2O, 3.7 +/- 1.4 in rats treated with EHEN alone, and 1.0 +/- 2.4 in rats treated with high Na3NTA X H2O diet alone. Atypical cell foci retained a tubular pattern and consisted of basophilic cells with a large nucleus or clear cells with a small nucleus.
Case 15-1983
Authors: Richard C. Cabot, Robert E. Scully, Eugene J. Mark, Betty U. McNeely, Burton D. Rose, Robert B. Colvin
Journal: New England Journal of Medicine (1983)

Presentation of CaseA 24-year-old man was admitted to the hospital because of cervical lymphadenopathy and the nephrotic syndrome.He was in excellent health until one month earlier, when he noticed an enlarged, nontender left cervical lymph node. At about the same time he lost his taste for cigarettes and discontinued the use of two packages daily. During the next four weeks the lymph node increased in size, and he observed periorbital swelling, followed by progressive pedal edema, abdominal distention, increased fatigue, and bilateral dull flank pain. During the two weeks before entry he experienced night sweats on several occasions. . . .
Combined Famd and ANOVA Investigation Leads to Significant Association Between the hOCT1/ABCB1 Diplotype and Both Efficacy and Tolerability in Patients Affected By Chronic Myeloid Leukemia
Authors: Sara Galimberti, Laura Galeotti, Francesco Ceccherini, Dario Domingo, Marco Laurino, Marialuisa Polillo, Antonello Di Paolo, Claudia Baratè, Carmen Fava, Antonio D'Avolio, Giulia Fontanelli, Romano Danesi, Fulvio Cornolti, Francesca Guerrini, Elena Ciabatti, Giuseppe Saglio, Mario Petrini
Journal: Blood (2015)
Motivational interviewing-based training enhances clinicians’ skills and knowledge in psoriasis: findings from the Pso Well<sup>®</sup>study
Authors: A. Chisholm, P.A. Nelson, C.J. Pearce, A.J. Littlewood, K. Kane, A.L. Henry, R. Thorneloe, M.P. Hamilton, J. Lavallee, M. Lunt, C.E.M. Griffiths, L. Cordingley, C. Bundy
Journal: British Journal of Dermatology (2016)

Psoriasis is a common long-term, immune-mediated skin condition associated with behavioural factors (e.g. smoking, excess alcohol, obesity), which increase the risk of psoriasis onset, flares and comorbidities. Motivational interviewing (MI) is an evidence-based approach to health-related behaviour change that has been used successfully for patients with long-term conditions. This study assessed change in clinicians' MI skills and psoriasis knowledge following Psoriasis and Wellbeing (Pso Well® ) training.To investigate whether the Pso Well training intervention improves clinicians' MI skills and knowledge about psoriasis-related comorbidities and risk factors; and to explore the acceptability and feasibility of the Pso Well training content, delivery and evaluation.Clinicians attended the 1-day training programme focused on MI skills development in the context of psoriasis. MI skills were assessed pre- and post-training using the Behaviour Change Counselling Index. Knowledge about psoriasis-related comorbidity and risk factors was assessed with a novel 22-point measure developed for the study. Interviews with clinicians were analysed qualitatively to identify perceptions about the feasibility and acceptability of the training.Sixty-one clinicians completed the training (35 dermatology nurses, 23 dermatologists and three primary-care clinicians). Clinicians' MI skills (P < 0·001) and knowledge (P < 0·001) increased significantly post-training. Clinicians found the training valuable and relevant to psoriasis management.Attendance at the Pso Well training resulted in improvements in clinicians' knowledge and skills to manage psoriasis holistically. Clinicians deemed the training itself and the assessment procedures used both feasible and acceptable. Future research should investigate how this training may influence patient outcomes.
The G-CSF Induced MiR-143 Targets MAPK-Family Proteins and Is a Prognostic Factor for RIC-Transplanted AML Patients
Authors: Jens-Uwe Hartmann, Daniela Braeuer-Hartmann, Dennis Gerloff, Christiane Katzerke, Alexander Arthur Wurm, Carsten Müller-Tidow, Sebastian Schwind, Daniel G. Tenen, Dietger Niederwieser, Gerhard Behre
Journal: Blood (2014)
Chronic Viral Infection, Virus-Specific Monoclonal Immunoglobulin, and Development of Plasma Cell Malignancy
Authors: Delphine Feron, Cathy Charlier, Victor Gourain, Marianne Coste, Philippe Moreau, Mohamed Hamidou, Laurent Garderet, Yannick Jacques, Pierre Weigel, Sylvie Hermouet, Edith Bigot-Corbel
Journal: Blood (2011)
Case 22-1969
Authors: Kenneth I. Shine, Benjamin Castleman
Journal: New England Journal of Medicine (1969)

Presentation of Case First admission. A seventy-six-year-old man was admitted to the hospital because of progressive fatigue and dyspnea.Several years previously a physician told him that he had hypertension and prescribed a low-sodium diet and medication. In recent years he had taken no medication. During the six months before admission he had ankle edema, with gradually progressive exertional dyspnea and orthopnea, and lost 31 pounds in weight. Four weeks before entry fatigue and severe dyspnea developed.There had been no pleuritic or anginal pain or episodes of palpitation. Many years previously he had been informed that he had an . . .
The Prognostic Impact of the Evolution of RV Function in Idiopathic DCM
Authors: Marco Merlo, Marco Gobbo, Davide Stolfo, Pasquale Losurdo, Federica Ramani, Giulia Barbati, Alberto Pivetta, Andrea Di Lenarda, Marco Anzini, Marta Gigli, Bruno Pinamonti, Gianfranco Sinagra
Journal: JACC. Cardiovascular imaging (2016)
XPO1 Inhibition using Selinexor Synergizes with Chemotherapy in Acute Myeloid Leukemia by Targeting DNA Repair and Restoring Topoisomerase IIα to the Nucleus
Authors: Parvathi Ranganathan, Trinayan Kashyap, Xueyan Yu, Xiaomei Meng, Tzung-Huei Lai, Betina McNeil, Bhavana Bhatnagar, Sharon Shacham, Michael Kauffman, Adrienne M. Dorrance, William Blum, Deepa Sampath, Yosef Landesman, Ramiro Garzon
Journal: Clinical Cancer Research (2016)

Selinexor, a selective inhibitor of XPO1, is currently being tested as single agent in clinical trials in acute myeloid leukemia (AML). However, considering the molecular complexity of AML, it is unlikely that AML can be cured with monotherapy. Therefore, we asked whether adding already established effective drugs such as topoisomerase (Topo) II inhibitors to selinexor will enhance its anti-leukemic effects in AML.The efficacy of combinatorial drug treatment using Topo II inhibitors (idarubicin, daunorubicin, mitoxantrone, etoposide) and selinexor was evaluated in established cellular and animal models of AML.Concomitant treatment with selinexor and Topo II inhibitors resulted in therapeutic synergy in AML cell lines and patient samples. Using a xenograft MV4-11 AML mouse model, we show that treatment with selinexor and idarubicin significantly prolongs survival of leukemic mice compared with each single therapy.Aberrant nuclear export and cytoplasmic localization of Topo IIα has been identified as one of the mechanisms leading to drug resistance in cancer. Here, we show that in a subset of patients with AML that express cytoplasmic Topo IIα, selinexor treatment results in nuclear retention of Topo IIα protein, resulting in increased sensitivity to idarubicin. Selinexor treatment of AML cells resulted in a c-MYC-dependent reduction of DNA damage repair genes (Rad51 and Chk1) mRNA and protein expression and subsequent inhibition of homologous recombination repair and increased sensitivity to Topo II inhibitors. The preclinical data reported here support further clinical studies using selinexor and Topo II inhibitors in combination to treat AML. Clin Cancer Res; 22(24); 6142-52. ©2016 AACR.
Health groups demand closure of Europe’s coal fired power stations
Authors: Rory Watson
Journal: BMJ (2016)

Coal fired power stations were responsible for over 20 000 premature deaths each year and tens of thousands of cases of ill health in Europe, according to new research by an alliance of four health and environmental non-governmental organisations (NGOs).1

The Health and Environment Alliance, Climate Action Network Europe, WWF European Policy Office, and Sandbag have demanded the closure of the European Union’s (EU) 280 coal fired power plants that currently produce 24% of its electricity. Such a policy decision, they said, would be in line with last year’s Paris UN climate summit goal to keep the global temperature rise to …
Prior Hypomethylating Agents Or Chemotherapy Does Not Improve The Outcome Of Allogeneic Hematopoietic Transplantation For High Risk MDS
Authors: Betul Oran, Piyanuch Kongtim, Marcos de Lima, Uday R Popat, Guillermo Garcia-Manero, Elias J. Jabbour, Lynne V. Abruzzo, Julianne Chen, Gabriela Rondon, Borje S. Andersson, Amin Alousi, Stefan O. Ciurea, Elizabeth J Shpall, Richard E Champlin
Journal: Blood (2013)
The affective experience of residency training in community psychiatry
Authors: P G Cotton, K D Pruett
Journal: American Journal of Psychiatry (1975)

The community setting arouses disturbing feelings (of anxiety, loneliness, anger, and disappointment) within the resident in a manner that is both unique and potentially constructive for his development as a clinician. The examination of these feelings in the supervisory setting and through peer supervision is crucial to the success of the resident's work in the community.